Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations

Bibliography

• Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. McGraw-Hill; New York: NY: 2001. p. 3421-52
   Google Scholar
• Tomatsu S, Montaño AM, Oikawa H, et al. Impairment of body growth in mucopolysaccharidoses, in handbook of growth and growth monitoring in health and disease 1. Springer; New York: 2012. p. 2091-117
   Google Scholar
• Patel P, Suzuki Y, Maeda M, et al. Growth charts for patients with Hunter syndrome. Mol Genet Metab Rep 2014;1:5-18
   PubMedGoogle Scholar
• Tomatsu S, Montaño AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol 2011;12:931-45
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Miller TL, Mackenzie WG, et al. Characteristics of impulse oscillometry and thoracoabdominal motion in children with thoracic cage disorders. Pediatr Pulmonol 2010;45:679-86
   PubMed Web of Science ®Google Scholar
• Theroux MC, Nerker T, Ditro C, Mackenzie WG. Anesthetic care and perioperative complications of children with Morquio syndrome. Paediatr Anaesth 2012;22:901-7
   PubMed Web of Science ®Google Scholar
• Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8
   Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-73
   PubMed Web of Science ®Google Scholar
• Montaño AM, Tomatsu S, Gottesman GS, et al. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis 2007;30:165-74
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Mackenzie WG, Theroux MC, et al. Current and emerging treatments and surgical interventions for Morquio A Syndrome: A review. Res Rep Endocr Disord 2012(2):65-77
   PubMedGoogle Scholar
• Orii T, Kiman T, Sukegawa K, et al. Late onset N-acetylgalactosamine-6-sulfate sulfatase deficiency in two brothers. Connect Tissue 1981;13:169-75
   Google Scholar
• Fujimoto A, Horwitz AL. Biochemical defect of non-keratan-sulfate-excreting Morquio syndrome. Am J Med Genet 1983;15(2):265-73
   PubMed Web of Science ®Google Scholar
• Beck M, Glössl J, Grubisic A, Spranger J. Heterogeneity of Morquio disease. Clin Genet 1986;29:325-31
   PubMed Web of Science ®Google Scholar
• Orii T, Minami R, Chiba T, et al. Study on morquio syndrome. Bone Metabolism (in Japanese) 1971;5:72-8
   Google Scholar
• Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis 2012;36:309-22
   PubMed Web of Science ®Google Scholar
• Yasuda E, Fushimi K, Suzuki Y, et al. Pathogenesis of morquio a syndrome: an autopsied case reveals systemic storage disorder. Mol Genet Metab 2013;109:301-11
   PubMed Web of Science ®Google Scholar
• Shimada T, Tomatsu S, Yasuda E, et al. Chondroitin 6-sulfate as a novel biomarker for mucopolysaccharidosis IVA and VII. JIMD Rep 2014;16:15-24
   PubMedGoogle Scholar
• Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis 2014;37:979-90
   PubMed Web of Science ®Google Scholar
• FDA Advisory Committee Briefing Document. Elosulfase alfa for Mucopolysaccharidosis Type IVA. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm375126.pdf
   Google Scholar
• Connock M, Juarez-Garcia A, Frew E, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type I. Health Technol Assess 2006;10:1-6
   Web of Science ®Google Scholar
• Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders : progress with enzyme replacement therapy. Drugs 2007;67:2697-716
   PubMed Web of Science ®Google Scholar
• Qi Y, Musson DG, Schweighardt B, et al. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome. Clin Pharmacokinet 2014;53:1137-47
   PubMed Web of Science ®Google Scholar
• Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91
   PubMed Web of Science ®Google Scholar
• Parveen S, Sahoo SK. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 2006;45:965-88
   PubMed Web of Science ®Google Scholar
• Dickson P, Peinovich M, McEntee M, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 2008;118:2868-76
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Dung VC, et al. Enhancement of drug delivery: enzyme replacement therapy for murine Morquio A syndrome. Mol Ther 2012;18:1094-102
   Web of Science ®Google Scholar
• Rowan DJ, Tomatsu S, Grubb JH, et al. Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Mol Genet Metab 2012;107:161-72
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Espejo AJ, Hernandez A, et al. Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21. J Ind Microbiol Biotechnol 2010;37:1193-201
   PubMed Web of Science ®Google Scholar
• Espejo-Mojica ÁJ, Alméciga-Díaz CJ, Rodríguez A, et al. Human recombinant lysosomal enzymes produced in microorganisms. Mol Genet Metab 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• . Sands MS, Barker JE, Vogler C, et al.et al. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest 1993;68:676-86
   PubMed Web of Science ®Google Scholar
• Soper BW, Lessard MD, Vogler CA, et al. Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency. Blood 2001;97:1498-504
   PubMed Web of Science ®Google Scholar
• Lau AA, Shamsani NJ, Winner LK, et al. Neonatal bone marrow transplantation in MPS IIIA Mice. JIMD Rep 2013;8:121-32
   PubMedGoogle Scholar
• Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with Hunter syndrome. Mol Genet Metab Rep 2014;1:184-96
   PubMedGoogle Scholar
• Tanjuakio J, Suzuki Y, Patel P, et al. Activities of Daily Living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Mol Genet Metab 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Alméciga-Díaz CJ, Montaño AM, et al. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab 2014; Epub ahead of print
   Google Scholar
• Tomatsu S, Yasuda E, Patel P, et al. Morquio A syndrome: diagnosis and current and future therapies. Pediatr Endocrinol Rev 2014;12(Suppl 1):141-51
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Alméciga-Díaz CJ, Barbosa H, et al. Therapies of Mucopolysaccharidosis IVA (Morquio A syndrome). Expert Opin Orphan Drugs 2013;1:805-18
   PubMed Web of Science ®Google Scholar
• Chinen Y, Higa T, Tomatsu S, et al. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep 2014;1:31-41
   PubMedGoogle Scholar
• Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on biphosphonic prodrug. I.v. effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. J Drug Target 1998;5:129-38
   PubMed Web of Science ®Google Scholar
• Sekido T, Sakura N, Higashi Y, et al. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Targeting 2001;9:111-21
   PubMed Web of Science ®Google Scholar
• Yokogawa K, Miya K, Sekido T, et al. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001;142:1228-33
   PubMed Web of Science ®Google Scholar
• Nishioka T, Tomatsu S, Gutierrez MA, et al. Targeted drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol Genet Metab 2006;88:244-55
   PubMed Web of Science ®Google Scholar
• Millán JL, Narisawa S, Lemire I, et al. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res 2008;23:777-87
   PubMed Web of Science ®Google Scholar
• Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med 2012;8:904-13
   Web of Science ®Google Scholar
• Oikawa H, Tomatsu S, Haupt B, et al. Enzyme replacement therapy on hypophosphatasia mouse model. J Inherit Metab Dis 2014;37:309-17
   PubMed Web of Science ®Google Scholar
• Montaño AM, Oikawa H, Tomatsu S, et al. Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Mol Genet Metab 2008;94:178-89
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Dung VC, et al. Enhancement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther 2010;18:1094-102
   PubMed Web of Science ®Google Scholar
• Paciotti S, Persichetti E, Pagliardini S, et al. First pilot newborn screening for four lysosomal storage diseases in an Italian region: identification and analysis of a putative causative mutation in the GBA gene. Clin Chim Acta 2012;413:1827-31
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Fujii T, Fukushi M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab 2013;110:42-53
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Orii KO, Vogler C, et al. Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet 2003;12:3349-58
   PubMed Web of Science ®Google Scholar
• Beck M, Braun S, Coerdt W, et al. Fetal presentation of Morquio disease type A. Prenat Diagn 1992;12:1019-29
   PubMed Web of Science ®Google Scholar
• Ohashi A, Montaño AM, Colón JE, et al. Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease. Acta Paediatr 2009;98:768-9
   PubMed Web of Science ®Google Scholar
• Muenzer J, Lamsa JC, Garcia A, et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002;91:98-9
   PubMedGoogle Scholar
• Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004;144:574-80
   PubMed Web of Science ®Google Scholar
• Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005;115:e681-9
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-9
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008;94:469-75
   PubMed Web of Science ®Google Scholar
• Dvorak-Ewell M, Wendt D, Hague C, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One 2010;5:e12194
   PubMed Web of Science ®Google Scholar
• Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008;167:267-77
   PubMed Web of Science ®Google Scholar
• Hendriksz C, Vellodi A, Jones S, et al. Long term outcomes of a phase1/2,multicenter, open-label,dose-escalationstudyto evaluate the safety, tolerability, and efficacy of BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A syndrome). Mol Genet Metab 2012;105:S35
   Web of Science ®Google Scholar
• Hendriks CJ, Giugliani R, Harmatz P, et al. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Shah MR, Hasselblad V, Gheorghiade M, et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol 2001;88:987-93
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92
   PubMed Web of Science ®Google Scholar
• Gulmans VA, van Veldhoven NH, de Meer K, et al. The six-minute walking test in children with cystic fibrosis: reliability and validity. Pediatr Pulmonol 1996;22:85-9
   PubMed Web of Science ®Google Scholar
• McDonald CM, Henricson EK, Han JJ, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010;41:500-10
   PubMed Web of Science ®Google Scholar
• Elloumi M, Makni E, Ounis OB, et al. Six-minute walking test and the assessment of cardiorespiratory responses during weight-loss programmes in obese children. Physiother Res Int 2011;16:32-42
   PubMedGoogle Scholar
• Tomatsu S, Montaño AM, Ohashi A, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 2008;17:815-24
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Oikawa H, et al. Enzyme replacement therapy in newborn mucopolysaccharidosis IVA mice: early treatment rescues bone lesions? Mol Genet Metab 2014; Epub ahead of print
   Google Scholar
• Oldberg A, Franzen A, Heinegard D. The primary structure of a cell-binding bone sialoprotein. J Biol Chem 1988;263:19430-2
   PubMed Web of Science ®Google Scholar
• Kasugai S, Fujisawa R, Waki Y, et al. Selective drug delivery system to bone: small peptide (Asp)6 conjugation. J Bone Miner Res 2000;15:936-43
   PubMed Web of Science ®Google Scholar
• Nagata T, Bellows CG, Kasugai S, et al. Biosysnthesis of bone proteins [SPP-1 (secreted phosphoprotein-1, osteopontin), BSP (bone sialoprotein) and SPARC (osteonectin) in association with mineralized-tissue formation by fetal-rat calvarian cells in culture. Biochem J 1991;274:513-20
   PubMed Web of Science ®Google Scholar
• Butler WT. The nature and significance of osteopontin. Connect Tissue Res 1989;23:123-36
   PubMed Web of Science ®Google Scholar
• Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol 2005;59:491-4
   PubMed Web of Science ®Google Scholar
• Aronson JK. Research priorities in biomarkers and surrogate end-points. Br J Clin Pharmacol 2012;73:900-7
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Sawamoto K, Alméciga-Díaz CJ, et al. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio a syndrome. Drug Des Devel Ther 2015;9:1937-53
   PubMed Web of Science ®Google Scholar
• Dorfman A, Arbogast B, Matalon R. The enzymic defects in Morquio and Maroteaux-Lamy syndrome. Adv Exp Med Biol 1976;68:261-76
   PubMedGoogle Scholar
• Glossl J, Kresse H. A sensitive procedure for the diagnosis of N-acetyl-galactosamine-6-sulfate sulfatase deficiency in classical Morquio’s disease. Clin Chim Acta 1978;88:111-19
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Okamura K, Taketani T, et al. Development and testing of new screening method for keratan sulfate in mucopolysaccharidosis IVA. Pediatr Res 2004;55:592-7
   PubMed Web of Science ®Google Scholar
• Oguma T, Tomatsu S, Okazaki O. Analytical method for determination of disaccharides derived from keratan sulfates in human serum and plasma by high-performance liquid chromatography/turbo-ionspray ionization tandem mass spectrometry. Biomed Chromatogr 2007;21:356-62
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Oguma T, et al. Validation of keratan sulfate level in Mucopolysaccharidosis IVA by liquid tandem mass spectrometry method. J Inherit Metab Dis 2010;33:Suppl 3 S35-42
   PubMed Web of Science ®Google Scholar
• Hintze JP, Tomatsu S, Fujii T, et al. Comparison of liquid chromatography-tandem mass spectrometry and sandwich ELISA for determination of keratan sulfate in plasma and urine. Biomark Insights 2011;6:69-78
   PubMedGoogle Scholar
• Martell LA, Cunico RL, Ohh J, et al. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis 2011;3:1855-66
   PubMed Web of Science ®Google Scholar
• Dũng VC, Tomatsu S, Montaño AM, et al. Mucopolysaccharidosis IVA: correlation between genotype, phenotype and keratan sulfate levels. Mol Genet Metab 2013;110:129-38
   PubMed Web of Science ®Google Scholar
• Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab 2013;109:54-61
   PubMed Web of Science ®Google Scholar
• Donida B, Marchetti DP, Biancini GB, et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta 2015;1852(5):1012-19
   PubMed Web of Science ®Google Scholar
• Shimada T, Tomatsu S, Mason RW, et al. Di-sulfated keratan sulfate as a novel biomarker for mucopolysaccharidosis IVA. J Inherit Metab Dis Reports 2014; In press
   Google Scholar